Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125823271 | 12582327 | 1 | I | 20160708 | 20160722 | 20160722 | EXP | CN-CIPLA LTD.-2016CN09756 | CIPLA | ZHOU HY, YANG C, QIN B, YUAN Z. META-ANALYSIS OF PROPHYLACTIC ENTECAVIR OR LAMIVUDINE AGAINST HEPATITIS B VIRUS REACTIVATION. ANNALS OF HEPATOLOGY. 2016;15(4):501 TO 511 | 0.00 | Y | 0.00000 | 20160722 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125823271 | 12582327 | 1 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | 100 MG, QD | U | U | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125823271 | 12582327 | 1 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125823271 | 12582327 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125823271 | 12582327 | Hepatitis B |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |